ペプチド治療薬市場：技術、薬剤クラス別、投与経路、用途、エンドユーザー、製造タイプ別-2025-2030年世界予測

ペプチド治療薬市場は、2023年に330億6,000万米ドルと評価され、2024年には357億6,000万米ドルに達すると予測され、CAGR 8.35％で成長し、2030年には579億7,000万米ドルになると予測されています。

ペプチド治療薬、バイオテクノロジーと製薬セクターの重要なセグメントでは、その高い特異性、安全性、有効性により、医薬品としてのペプチドの使用に焦点を当てています。この天然に存在する生体分子は、アミノ酸の短い鎖で構成され、主に腫瘍学、代謝性疾患、感染症などの分野に対応しています。ペプチド治療薬の必要性は、従来の低分子医薬品と比較して副作用が少なく、疾患経路を正確に標的とする能力から生じています。ドラッグデリバリーシステム、がん免疫療法、抗菌剤などに応用されています。主なエンドユーザーは、病院、専門クリニック、研究機関、製薬会社などです。市場成長の原動力は、生物学的に活性なペプチドの研究拡大、慢性疾患の蔓延、ペプチド合成とドラッグデリバリー技術の進歩です。特に個別化医療や再生療法では、ペプチド工学やナノテクノロジーの技術革新によって機会が熟しています。学術研究センターと製薬会社の協力により、新規用途がさらに発見される可能性があります。しかし、市場の拡大は、高い製造コスト、ペプチドの安定性とデリバリーにおける複雑さ、研究開発プロセスを阻害する厳しい規制のハードルといった課題に直面しています。さらに、競合情勢はバイオテクノロジーの進歩の絶え間ない流入によって激化しており、機敏な研究戦略が必要とされています。ペプチドベースのワクチンや診断薬など、需要が急増している分野にはビジネスチャンスが存在します。固相ペプチド合成の開発など化学合成の進歩は、現在の生産とコストの限界を克服する道筋を提示します。企業は、包括的な専門知識とリソースの共有を活用するために、多部門とのパートナーシップに焦点を当てるべきです。市場のダイナミックな性質は、画期的な治療法の可能性を強調するものであり、治療用ペプチドの安定性とデリバリー・メカニズムの拡大を目指した現在進行中の研究が、新たな成長の道を切り開く可能性が高いです。このような革新的な分野を探求することは、治療アプローチを重要な方法で再構築することを約束します。

市場力学：急速に進化するペプチド治療薬市場の主要市場インサイトを公開

ペプチド治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の流行と効果的な治療オプションの必要性
  • 美容皮膚科学におけるペプチドの利用拡大
• 市場抑制要因
  • ペプチド治療薬の不都合なリコール
• 市場機会
  • 世界の新規ペプチド開発のための継続的な研究開発活動
  • 個別化医療へのシフトとペプチドバイオマーカーの特定
• 市場の課題
  • ペプチド治療薬の生産の複雑さとバイオアベイラビリティの問題

ポーターの5つの力：ペプチド治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、ペプチド治療薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ペプチド治療薬市場における外部からの影響の把握

外部マクロ環境要因は、ペプチド治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ペプチド治療薬市場における競合情勢の把握

ペプチド治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスペプチド治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ペプチド治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の蔓延と効果的な治療法の必要性
    • 美容皮膚科におけるペプチドの急激な増加
  • 抑制要因
    • ペプチド治療薬の悪影響の想起
  • 機会
    • 世界中で新規ペプチド開発に向けた研究開発活動を継続中
    • 個別化医療への移行とペプチドバイオマーカーの特定
  • 課題
    • ペプチド治療薬の生産の複雑さと生物学的利用能の問題
• 市場セグメンテーション分析
  • 技術：複合ペプチドの合成における固相法の利用増加
  • 薬物クラス：1型および2型糖尿病のグルコース代謝を調節するためのインスリンの必要性の増加
  • 投与経路：急性期病院治療環境では、即時性と有効性のため静脈内投与の採用が増加しています。
  • 応用：血圧調節に関与する内因性ペプチドの作用をシミュレートするために、心血管疾患におけるペプチド治療薬の幅広い使用
  • エンドユーザー：患者の状態に対応し管理するために病院や診療所でペプチド治療薬の使用を拡大する
  • 製造タイプ：専門的な製造能力と生産を迅速に拡大する能力の必要性から、CMOの採用が増加しています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ペプチド治療薬市場：技術別

• ハイブリッドフェーズ
• 液相
• 固相

第7章 ペプチド治療薬市場薬剤クラス別

• 副腎皮質刺激ホルモン
• カルシトニン
• インスリン
• リュープロレリン
• オクトレオチド
• バソプレシン

第8章 ペプチド治療薬市場：投与経路別

• 静脈内投与
• 経鼻・経肺投与
• 経口投与
• 経皮投与

第9章 ペプチド治療薬市場：用途別

• 心血管疾患
• 胃腸障害
• 感染症
• 神経疾患
• 腫瘍学

第10章 ペプチド治療薬市場：エンドユーザー別

• 病院・クリニック
• 長期介護施設
• 調査室

第11章 ペプチド治療薬市場製造タイプ別

• 契約製造組織
• 社内

第12章 南北アメリカのペプチド治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域のペプチド治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカのペプチド治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ノバルティスとペプチドリームは、1億8,000万米ドルと28億米ドルの契約で先進的な腫瘍治療薬の開発に協力しました。
  • コーデンファーマ・フランクフルトのGMP能力の拡大：初期段階のペプチドAPI製造の向上
  • ペプチド治療の革命：オルビス・メディシンズが経口ドラッグデリバリーの革新を実現
  • コペンハーゲンのオルビス・メディシンズは、経口バイオアベイラビリティを高める先進的なマクロ環式技術を搭載したペプチド治療薬を発売しました。
  • ペプチド治療薬生産施設の拡大：WuXi AppTecの戦略的成長
  • グレンマーク・ファーマシューティカルズ、糖尿病治療に革命を起こすバイオシミラーのリラグルチドをインドで発売すると発表
  • アミドテクノロジーズの革新的な製造プラットフォームと戦略的資本の前進
  • 戦略的買収によりPharmathenの地位が向上ペプチド治療薬市場
  • バイオシンス、ペプシューティカルズの戦略的買収により市場での地位を強化
  • ペプチドリームとジェネンテックがペプチド放射性同位元素治療の発展に向けて戦略的提携
  • メルクとIRBMがペプチド治療薬分野で前進：バイオ医薬品の拡大と革新に向けた提携
  • 富士通、がんおよび中枢神経系再生の進歩に重点を置いた先駆的なバイオ医薬品設計アクセラレータを発表
  • シンクレストCRDMOサービス導入による構想から製造までの開発を総合的にサポート

企業一覧

• AbbVie Inc.
• AmbioPharm, Inc.
• Amgen Inc.
• Amide Technologies, Inc.
• AstraZeneca PLC
• Bachem Holding AG
• Biosynth Ltd.
• Bristol Myers Squibb Company
• Cidara Therapeutics, Inc.
• Corden Pharma International GmbH
• Cybrexa, Inc.
• Eccogene
• Eli Lilly and Company
• Exelixis, Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Ipsen Group
• IRBM S.p.A.
• Ironwood Pharmaceuticals, Inc.
• Merck KGaA
• Novartis AG
• Novo Nordisk A/S
• Otsuka Pharmaceutical Co., Ltd.
• Peptidream Co., Ltd.
• Perpetual Medicines Corporation
• Pfizer Inc.
• Piramal Pharma Limited
• PolyPeptide Group AG
• RELIEF THERAPEUTICS Holding SA
• Sanofi S.A.
• Sanyou Biopharmaceuticals Co., Ltd.
• Shanghai Full-Life Technologies Co, Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Limited
• WuXi AppTec Co., Ltd.
• Zealand Pharma A/S

LIST OF FIGURES

• FIGURE 1. PEPTIDE THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. PEPTIDE THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PEPTIDE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PEPTIDE THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LEUPRORELIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NASAL & PULMONARY ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 55. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 56. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 87. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 88. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 93. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 95. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 183. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 189. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 195. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 196. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 197. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 198. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 201. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 207. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 213. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 219. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 220. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 221. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 222. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 223. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 224. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 225. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 226. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 227. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 228. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 229. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 231. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 237. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 243. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 255. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 261. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 267. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 273. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 279. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 284. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 285. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
• TABLE 286. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 287. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Peptide Therapeutics Market was valued at USD 33.06 billion in 2023, expected to reach USD 35.76 billion in 2024, and is projected to grow at a CAGR of 8.35%, to USD 57.97 billion by 2030.

Peptide therapeutics, a vital segment within the biotechnology and pharmaceutical sectors, focus on the use of peptides as drugs due to their high specificity, safety, and efficacy. These naturally occurring biological molecules, consisting of short chains of amino acids, cater primarily to areas such as oncology, metabolic disorders, and infectious diseases. The necessity for peptide therapeutics arises from their ability to precisely target disease pathways with fewer side effects compared to traditional small molecule drugs. They find application in drug delivery systems, cancer immunotherapy, and as antimicrobial agents. Key end-users include hospitals, specialized clinics, research institutes, and pharmaceutical companies. Market growth is driven by expanding research into biologically active peptides, escalating prevalence of chronic diseases, and advancements in peptide synthesis and drug delivery technologies. Opportunities are ripe, especially in personalized medicine and regenerative therapies, enhanced by innovations in peptide engineering and nanotechnology. Collaboration between academic research centers and pharmaceutical companies can further uncover novel applications. However, market expansion faces challenges such as high production costs, complexities in peptide stability and delivery, and stringent regulatory hurdles that can impede R&D processes. Additionally, the competitive landscape is intensified by the constant influx of biotechnological advancements, necessitating agile research strategies. Opportunities exist in areas like peptide-based vaccines and diagnostics where demand is burgeoning. Advances in chemical synthesis, such as the development of solid-phase peptide synthesis, present pathways for overcoming current production and cost limitations. Firms should focus on multisector partnerships to leverage comprehensive expertise and resource sharing. The market's dynamic nature underscores the potential for groundbreaking treatments, with ongoing research directed at expanding therapeutic peptides' stability and delivery mechanisms likely to usher in new growth avenues. Exploring these areas for innovation promises to reshape therapeutic approaches in significant ways.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Peptide Therapeutics Market

The Peptide Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of chronic diseases and need for effective therapeutic options
  • Exponential use of peptides in aesthetic dermatology
• Market Restraints
  • Adverse recalls of peptide therapeutics
• Market Opportunities
  • Ongoing R&D activities for new peptide development worldwide
  • Shift toward personalized medicine and identification of peptide biomarkers
• Market Challenges
  • Production complexity and bioavailability issues of peptide therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Peptide Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Peptide Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Peptide Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Peptide Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Peptide Therapeutics Market

A detailed market share analysis in the Peptide Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Peptide Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Peptide Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Peptide Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AmbioPharm, Inc., Amgen Inc., Amide Technologies, Inc., AstraZeneca PLC, Bachem Holding AG, Biosynth Ltd., Bristol Myers Squibb Company, Cidara Therapeutics, Inc., Corden Pharma International GmbH, Cybrexa, Inc., Eccogene, Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ipsen Group, IRBM S.p.A., Ironwood Pharmaceuticals, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Peptidream Co., Ltd., Perpetual Medicines Corporation, Pfizer Inc., Piramal Pharma Limited, PolyPeptide Group AG, RELIEF THERAPEUTICS Holding SA, Sanofi S.A., Sanyou Biopharmaceuticals Co., Ltd., Shanghai Full-Life Technologies Co, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, WuXi AppTec Co., Ltd., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Peptide Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Hybrid Phase, Liquid Phase, and Solid Phase.
• Based on Drug Class, market is studied across Adrenocorticotropic Hormone, Calcitonin, Insulin, Leuprorelin, Octreotide, and Vasopressin.
• Based on Route of Administration, market is studied across Intravenous Administration, Nasal & Pulmonary Administration, Oral Administration, and Transdermal Administration.
• Based on Application, market is studied across Cardiovascular Disorders, Gastrointestinal Disorders, Infectious Disorders, Neurological Disorders, and Oncology.
• Based on End User, market is studied across Hospitals & Clinics, Long-term Care Facilities, and Research Laboratories.
• Based on Manufacturing Type, market is studied across Contract Manufacturing Organization and In-house.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Indiana, Maryland, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of chronic diseases and need for effective therapeutic options
    • 5.1.1.2. Exponential use of peptides in aesthetic dermatology
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse recalls of peptide therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing R&D activities for new peptide development worldwide
    • 5.1.3.2. Shift toward personalized medicine and identification of peptide biomarkers
  • 5.1.4. Challenges
    • 5.1.4.1. Production complexity and bioavailability issues of peptide therapeutics
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Rising utilization of solid phase approach for synthesis of complex peptides
  • 5.2.2. Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes
  • 5.2.3. Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings
  • 5.2.4. Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation
  • 5.2.5. End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions
  • 5.2.6. Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Peptide Therapeutics Market, by Technology

• 6.1. Introduction
• 6.2. Hybrid Phase
• 6.3. Liquid Phase
• 6.4. Solid Phase

7. Peptide Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Adrenocorticotropic Hormone
• 7.3. Calcitonin
• 7.4. Insulin
• 7.5. Leuprorelin
• 7.6. Octreotide
• 7.7. Vasopressin

8. Peptide Therapeutics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Intravenous Administration
• 8.3. Nasal & Pulmonary Administration
• 8.4. Oral Administration
• 8.5. Transdermal Administration

9. Peptide Therapeutics Market, by Application

• 9.1. Introduction
• 9.2. Cardiovascular Disorders
• 9.3. Gastrointestinal Disorders
• 9.4. Infectious Disorders
• 9.5. Neurological Disorders
• 9.6. Oncology

10. Peptide Therapeutics Market, by End User

• 10.1. Introduction
• 10.2. Hospitals & Clinics
• 10.3. Long-term Care Facilities
• 10.4. Research Laboratories

11. Peptide Therapeutics Market, by Manufacturing Type

• 11.1. Introduction
• 11.2. Contract Manufacturing Organization
• 11.3. In-house

12. Americas Peptide Therapeutics Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Peptide Therapeutics Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Peptide Therapeutics Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Novartis and PeptiDream collaborated to develop advanced oncology therapies with a USD 180 million deal a USD 2.8 billion deal
  • 15.3.2. Expansion of GMP Capacities at CordenPharma Frankfurt: Elevating Early-Phase Peptide API Manufacturing
  • 15.3.3. Revolutionizing Peptide Therapeutics: Orbis Medicines Innovates for Oral Drug Delivery
  • 15.3.4. Copenhagen's Orbis Medicines launched peptide therapeutics with advanced macrocyclic technology for enhanced oral bioavailability
  • 15.3.5. Expanding Facilities in Peptide Therapeutic Production: WuXi AppTec's Strategic Growth
  • 15.3.6. Glenmark Pharmaceuticals Announces Biosimilar Liraglutide Launch in India to Revolutionize Anti-Diabetic Treatment
  • 15.3.7. Amide Technologies' Novel Manufacturing Platform and Strategic Capital Advancement
  • 15.3.8. Strategic Acquisition Elevates Pharmathen's Position in the Peptide Therapeutics Market
  • 15.3.9. Biosynth Solidifies Market Position with Strategic Acquisition of Pepceuticals
  • 15.3.10. Strategic Collaboration between PeptiDream and Genentech to Advance Peptide-Radioisotope Therapeutics
  • 15.3.11. Merck and IRBM Forge Forward in Peptide Therapeutics: A Partnership to Expand and Innovate in Biopharmaceuticals
  • 15.3.12. Fujitsu Launches Pioneering Bio-Drug Design Accelerator Focused on Advancing Peptide Therapeutics in Cancer and CNS Regeneration
  • 15.3.13. Comprehensive Support for Peptide Therapeutics Development from Conception to Manufacturing for Introducing SynCrest's CRDMO Service

Companies Mentioned

• 1. AbbVie Inc.
• 2. AmbioPharm, Inc.
• 3. Amgen Inc.
• 4. Amide Technologies, Inc.
• 5. AstraZeneca PLC
• 6. Bachem Holding AG
• 7. Biosynth Ltd.
• 8. Bristol Myers Squibb Company
• 9. Cidara Therapeutics, Inc.
• 10. Corden Pharma International GmbH
• 11. Cybrexa, Inc.
• 12. Eccogene
• 13. Eli Lilly and Company
• 14. Exelixis, Inc.
• 15. F. Hoffmann-La Roche Ltd.
• 16. GlaxoSmithKline PLC
• 17. Ipsen Group
• 18. IRBM S.p.A.
• 19. Ironwood Pharmaceuticals, Inc.
• 20. Merck KGaA
• 21. Novartis AG
• 22. Novo Nordisk A/S
• 23. Otsuka Pharmaceutical Co., Ltd.
• 24. Peptidream Co., Ltd.
• 25. Perpetual Medicines Corporation
• 26. Pfizer Inc.
• 27. Piramal Pharma Limited
• 28. PolyPeptide Group AG
• 29. RELIEF THERAPEUTICS Holding SA
• 30. Sanofi S.A.
• 31. Sanyou Biopharmaceuticals Co., Ltd.
• 32. Shanghai Full-Life Technologies Co, Ltd.
• 33. Takeda Pharmaceutical Company Limited
• 34. Teva Pharmaceutical Industries Limited
• 35. WuXi AppTec Co., Ltd.
• 36. Zealand Pharma A/S